The Diabetes Market Outlook To 2014

Market Dynamics, Competitive Landscape, Emerging Therapies

Publication Date	September 2009
Publisher	Business Insights
Product Type	Report
Pages	155
ISBN Number	not applicable
Product Code	RBI00338

Buy this product or for assistance call +44 20 7060 7474

PDF £2,305.00$3834 | €2580

PRINT £2,365.00$3934 | €2647

FAX Order above formats by FAX

Summary

Diabetes mellitus is a chronic metabolic disorder that results due to a failure of the body to produce the hormone insulin and/or an inability of the body to respond adequately to circulating insulin. Type 1 diabetes, previously referred to as insulin-dependent diabetes mellitus (IDDM), occurs most commonly in children or young adults and constitutes 5??

Content

Executive summary
- Patient potential
- Global market analysis
- Pipeline analysis
- Leading players of the global diabetes market
Chapter 1 Scope and methodology
- Scope
- Methodology
- Scope of IMS data
Chapter 2 Patient potential
- Summary
- Introduction
- What is diabetes?
- Types of diabetes
- Type 1 diabetes
- Type 2 diabetes
- Gestational diabetes mellitus
- Impaired glucose tolerance
- Diabetic complications
- Epidemiology
- Diagnosis
- How is diabetes measured?
- Treatment algorithm
Chapter 3 Global market analysis
- Summary
- Introduction
- Market analysis by country
- Licensing trends
- Key events/trends in the diabetes market
- FDA's revised guidelines on longer, larger cardiovascular risk studies for diabetes drugs
- Newer agents recommended by NICE in diabetes treatment
- A prophylactic treatment for children at high risk
- GSK discontinued development of remogliflozin
- Takeda's Phase II loss of TAK-379
- Novo Nordisk's Prandin lawsuit
- Market analysis by drug class
- Diabetes drug classes
- The insulin landscape
- Human insulins
- Animal insulins
- Drugs targeting underlying causes
- Glitazones
- Sulfonylurea
- Biguanides
- DPP-IV inhibitors
- Alpha-glucosidase inhibitors
- Glinides
- Glucagon-like peptide-1 agonists
- DPP-IV and GLP-1 differences
- Insulin devices
- Insulin pump therapy
- Therapy area sales forecast
- Leading brands of the diabetes market
- Generic erosion among the leading brands
- Leading brands sales forecast
Chapter 4 Pipeline analysis
- Summary
- Introduction
- Emerging trends/key events in diabetes R&D
- Emerging therapies in the diabetes market
- Inhaled insulin still a distant reality
- Hitherto unexplored avenues in diabetes R&D: magnesium, chromium and vanadium
- SGLT-2 inhibitors yet to prove their potential
- Other novel mechanisms under development
- Profiles of key pipeline products
- Drugs under registration/recently approved
- Victoza (liraglutide): Novo Nordisk
- Onglyza (saxagliptin): BMS/AstraZeneca
- SYR322 (alogliptin): Takeda
- Byetta LAR (exenatide long-acting release): Eli Lilly, Amylin,
- Alkermes
- Syncria (albiglutide): GlaxoSmithKline
- Ondero (linagliptin): Boehringer Ingelheim
- R1583 (taspoglutide): Roche/Ipsen
- AVE0010/ZP10: Sanofi-Aventis
- BMS-512148 (dapagliflozin): AstraZeneca/BMS
- Teplizumab: Eli Lilly/MacroGenics
- Competitive dynamics of the investigational drugs
- Key pipeline compounds sales forecast
Chapter 5 Leading players of the global diabetes market
- Summary
- Introduction
- Detailed analysis of the diabetes market players
- Novo Nordisk
- Overview
- Drug class focus
- Marketed product portfolio
- R&D pipeline analysis
- Novo Nordisk: strategic growth analysis
- Takeda
- Overview
- Drug class focus
- Marketed product portfolio
- R&D pipeline analysis
- Takeda: strategic growth analysis
- Sanofi-Aventis
- Overview
- Drug class focus
- Marketed products portfolio
- R&D pipeline analysis
- Sanofi-Aventis: strategic growth analysis
- Eli Lilly
- Overview
- Drug class focus
- Marketed products portfolio
- R&D pipeline analysis
- Eli Lilly: strategic growth analysis
- Merck & Co
- Overview
- Drug class focus
- Marketed products portfolio
- R&D pipeline analysis
- Merck: Strategic growth analysis
- Other major players in the diabetes market
- GSK
- Boehringer Ingelheim
- Leading players' outlook through to 2014
Chapter 6 Appendix
- IMS data
- Glossary
- Index
List of Figures
- Figure 2.1: Production of insulin and its action
- Figure 2.2: Diabetes treatment algorithm
- Figure 3.3: Global market sizes, 2008
- Figure 3.4: Global sales of types of diabetes brands ($m), 2008
- Figure 3.5: Relative positions of different types of insulins in the insulin market, 2008
- Figure 3.6: Relative positions of different diabetes drug classes, 2008
- Figure 4.7: Leading late-stage R&D products in the diabetes market, 2009
- Figure 5.8: Competitive dynamics of the top 10 diabetes players, 2007??